Suven to present results from Phase-2a study of Ropanicant at Neuroscience 2024
Suven plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.